Publication: 4494

Publication: 4494

Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602).

Google Scholar

Citation:

Meeting Instance:: ASCO GI 2025
Year:: 2025
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Exelixis
Grants:: U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN), U10CA180868 (NRG Oncology), U10CA180888 (SWOG)

Corr. Author:
Authors:: Jonathan R Strosberg Tyler Zemla Susan Geyer Michael V Knopp Spencer Behr Sydney Pulsipher Jared Acoba Ardaman Shergill Edward M Wolin Thorvardur R Halfdanarson Bhavana Konda Nikolaos A Trikalinos Bernard Tawfik Nitya Raj Shagufta Shaheen Namrata Vijayvergia Arvind Dasari Eileen M O'Reilly Jeffrey A Meyerhardt Jennifer A Chan

Networks:: CA824, FL065, HAWAII, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, NEWMEXICO, NY021

Study: Alliance-A021602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: